NPPA Sets Retail Prices for 80 New Drugs
The National Pharmaceutical Pricing Authority (NPPA), under the Ministry of Chemicals and Fertilizers, has announced the fixation of retail prices for 80 new drug formulations, aiming to ensure affordability and accessibility for consumers.
NPPA Fixes Retail Price for Cilnidipine & Telmisartan Tablets
Each film coated Cilnidipine & Telmisartan Tablet shall bear the retail price of Rs. 14.15. This price applies to tablets manufactured by M/s Akums Drugs & Pharmaceuticals Ltd. and marketed by M/s Glenmark Pharmaceuticals Limited.
NPPA Revises Ceiling Prices of Azithromycin & Amoxicillin + Clavulanic Acid
Manufacturers selling these formulations (branded or generic) above the revised ceiling price (plus applicable GST) must immediately revise their prices downwards to comply. Retailers and dealers must prominently display the price list provided by the manufacturer.
NPPA Fixes Retail Prices For 42 Formulations
The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices for 42 pharmaceutical formulations. These prices are exclusive of Goods and Services Tax, if applicable. These prices were notified on February 7, 2025.
India’s Drug Pricing Policy Focuses on Essentiality and Market-Based Mechanisms
The policy emphasizes several key principles, including regulating prices based on the essentiality of drugs, focusing price controls on consumer-level formulations (medicines) rather than bulk drugs or intermediates, and using market-based pricing mechanisms instead of cost-based pricing.
NPPA Fixes Retail Prices For 65 Formulations
The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices for 65 pharmaceutical formulations. The retail price for these specified formulations must match the specified price. Manufacturers are required to submit a price list in Form–V via IPDMS to the National Pharmaceutical Pricing Authority (NPPA) and provide copies to State Drug Controllers and dealers.
NPPA Revises Ceiling Prices for Scheduled Formulations
The National Pharmaceutical Pricing Authority (NPPA) has issued an order fixing ceiling prices for several essential medicines and revising prices for others based on a review order. The new prices, effective from December 19, 2024, aim to ensure affordability and accessibility of essential drugs.
Anti-Cancer Drugs to Become More Affordable
The National Pharmaceutical Pricing Authority (NPPA) has directed manufacturers to reduce the Maximum Retail Price (MRP) of Trastuzumab, Osimertinib, and Durvalumab. This reduction in MRP is a result of the government’s initiative to exempt these drugs from customs duty and reduce GST rates.
NPPA Extends Ceiling Prices for Orthopaedic Knee Implants
The NPPA has decided to continue the current ceiling prices for primary and secondary knee replacement systems. The specific ceiling prices for primary and secondary knee replacement systems will remain unchanged for another year, i.e. from September 16, 2024 to September 15, 2025, or until the next revision.
NPPA Fixes Retail Prices For 62 Formulations
The order specifies the retail prices for a total of 62 new drugs for specified strengths and manufacturers. These prices are exclusive of Goods and Services Tax, if applicable. Manufacturers are required to submit a price list in Form–V via IPDMS to the National Pharmaceutical Pricing Authority (NPPA) and provide copies to State Drug Controllers and dealers.
